Solara Active Pharma Sciences Ltd Q1 FY27 Earnings Analysis

- The company expects growth momentum mainly from its base business, focusing on expanding existing products and customers rather than ibuprofen or CRAMS, which remain subscale. - New product filings through R&D (4-5 DMFs annually) will start contributing around FY29-FY30, driving medium- to long-term growth. - Incremental revenue growth will be supported by better operational efficiency, yield improvement, and capacity debottlenecking within existing facilities (around 30% spare capacity available). - The company prefers investing resources in high-margin base business rather than commodity segments like ibuprofen, which have shown negative returns. - Management is hopeful to sustain and improve the recent positive quarterly performance and aims for 15-20% plus growth in the near term but is cautious about giving explicit guidance. - Long-term strategic growth will be driven by new geographies, increased market share, and enhanced product pipeline, supported by a strong leadership team.

- The company does not provide explicit future earnings or EPS guidance but expresses optimism about sustaining and improving current performance. - Q4 FY26 saw strong momentum with 12% QoQ revenue growth and 65% QoQ EBITDA growth, driven by the base business operating at ~26% EBITDA margin and 54% gross margins. - The base business is expected to continue driving growth, focusing on increasing market share, operational efficiency, and capacity utilization in existing facilities without large capex. - Incremental capex is limited to debottlenecking for high-margin products; no major greenfield expansions planned. - R&D revival includes plans to file 4-5 new DMFs per year from FY27, with revenue impact expected by FY29-FY30. - The company targets becoming debt-free by FY29, supporting financially stable growth. - The ibuprofen business is generating negative EBITDA; strategic options are being evaluated with outcomes expected in the next two quarters, impacting future profit dynamics.

- No large greenfield capex planned; focus is on utilizing existing capacity (around 30% spare capacity available). - Incremental capex being done to debottleneck lines for high-margin products and improve cycle times. - No big capex projects; emphasis on "smart and wise" use of existing capacity. - No current plans for additional capital raising beyond the recent rights issue; company aims to be debt-free by FY '29. - Vizag facility mothballed; future use under strategic evaluation (options include potentially repositioning as multipurpose or high-potent API block). - R&D investment of about INR 25 crores annually starting FY '26, to file 4–5 new DMFs per year with commercial impact expected FY '29 onwards. - The ibuprofen business may require strategic decisions including potential sale or technology change but no major capex planned there under current approach.

- After the recently completed rights issue, there are no further plans to raise additional capital through equity or debt at this time. (Page 13) - The company aims to become debt-free by FY '29, targeting both long-term and working capital debt elimination. (Page 13) - No major future fundraising activities for growth or debt paydown are expected in the next 2-3 years based on current plans. (Page 13)

- The base business of Solara has a very healthy order book, which is encouraging for sustained performance. - There is no specific quantitative figure disclosed for the current order book size. - The company is focused on expanding the existing business by seeding new customers for existing products, indicating ongoing and future orders. - CRAMS business remains subscale with annual revenues around INR 10-12 crores and lacks a strong order pipeline currently. - New product filings (4-5 DMFs annually) are planned, but meaningful revenue impact from these is expected around FY29-FY30. - Vizag facility remains mothballed; no current revenues; strategic options for this facility and ibuprofen business are under evaluation with clarity expected by H1 FY27. - Utilization across existing facilities is around 70%, leaving approximately 30% capacity to absorb incremental orders without significant new capex.